Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS), a clinical-stage biopharmaceutical company, is focused on improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing two potentially complementary agents for the treatment of chronic hepatitis C: ANA598, a non-nucleoside polymerase inhibitor; and ANA773, an oral TLR7 agonist prodrug. For further information, visit the Company’s web site at www.anadyspharma.com.
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS)
November 3, 2008 at 4:15am
Archives
Select A Month
